
Profound Medical Corp. PROF
$ 5.77
-1.37%
Annual report 2023
added 12-27-2025
Profound Medical Corp. Total Assets 2011-2026 | PROF
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Profound Medical Corp.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 43.9 M | 64.4 M | 86.8 M | 105 M | - | - | 27.9 M | 17.6 M | 15.3 M | 1.47 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 105 M | 1.47 M | 45.2 M |
Quarterly Total Assets Profound Medical Corp.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 86.8 M | - | - | - | 105 M | - | - | - | 30.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 105 M | 30.1 M | 73.8 M |
Total Assets of other stocks in the Medical devices industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Aethlon Medical
AEMD
|
7.36 M | $ 2.21 | -0.43 % | $ 3.45 M | ||
|
Alphatec Holdings
ATEC
|
791 M | $ 12.93 | -0.92 % | $ 1.94 B | ||
|
Acutus Medical
AFIB
|
54 M | - | -26.83 % | $ 2.62 M | ||
|
Allied Healthcare Products
AHPI
|
19.7 M | - | 3.58 % | $ 2.21 M | ||
|
AdaptHealth Corp.
AHCO
|
4.32 B | $ 10.53 | 0.77 % | $ 1.42 B | ||
|
ClearPoint Neuro
CLPT
|
97.7 M | $ 9.69 | -13.17 % | $ 274 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
224 M | - | - | $ 1.77 B | ||
|
Cytosorbents Corporation
CTSO
|
47.4 M | $ 0.66 | -2.96 % | $ 35.9 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
10.6 M | - | -5.86 % | $ 30.6 M | ||
|
EDAP TMS S.A.
EDAP
|
86.1 M | $ 3.82 | -5.91 % | $ 142 M | ||
|
Avinger
AVGR
|
13.8 M | - | -20.74 % | $ 369 K | ||
|
Cognyte Software Ltd.
CGNT
|
498 M | $ 8.32 | -0.48 % | $ 597 M | ||
|
Establishment Labs Holdings
ESTA
|
357 M | $ 65.54 | 0.81 % | $ 1.94 B | ||
|
Aziyo Biologics
AZYO
|
62.4 M | - | 1.37 % | $ 20.5 M | ||
|
Butterfly Network
BFLY
|
256 M | $ 4.06 | -4.92 % | $ 859 M | ||
|
BIOLASE
BIOL
|
35.1 M | - | -13.19 % | $ 166 K | ||
|
Conformis
CFMS
|
94 M | - | - | $ 16.4 M | ||
|
Boston Scientific Corporation
BSX
|
43.7 B | $ 70.78 | -0.59 % | $ 105 B | ||
|
Apollo Endosurgery
APEN
|
110 M | - | - | $ 475 M | ||
|
CONMED Corporation
CNMD
|
2.33 B | $ 37.4 | 0.16 % | $ 1.16 B | ||
|
CryoLife, Inc.
CRY
|
789 M | - | -4.14 % | $ 702 M | ||
|
Cutera
CUTR
|
346 M | - | -10.19 % | $ 1.99 M | ||
|
InMode Ltd.
INMD
|
766 M | $ 13.57 | -0.62 % | $ 877 M | ||
|
IRIDEX Corporation
IRIX
|
34.4 M | $ 1.33 | - | $ 21.5 M | ||
|
Dynatronics Corporation
DYNT
|
15.4 M | - | 14.99 % | $ 929 K | ||
|
Axonics Modulation Technologies
AXNX
|
659 M | - | - | $ 3.31 B | ||
|
Soliton, Inc.
SOLY
|
33.8 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
10.5 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
64.1 M | - | 0.03 % | $ 1.58 B | ||
|
OrthoPediatrics Corp.
KIDS
|
509 M | $ 16.8 | -2.38 % | $ 394 M | ||
|
Misonix, Inc.
MSON
|
204 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
66.2 M | - | - | $ 111 M | ||
|
FONAR Corporation
FONR
|
199 M | $ 18.44 | -0.05 % | $ 121 M | ||
|
Intersect ENT, Inc.
XENT
|
227 M | - | - | $ 955 M | ||
|
GBS
GBS
|
8.25 M | - | -0.57 % | $ 7.12 M | ||
|
Abbott Laboratories
ABT
|
86.7 B | $ 109.06 | -1.49 % | $ 190 B | ||
|
Delcath Systems
DCTH
|
124 M | $ 9.49 | -2.57 % | $ 340 M | ||
|
Bio-Rad Laboratories
BIO
|
9.36 B | $ 269.13 | -0.13 % | $ 7.59 B | ||
|
Helius Medical Technologies
HSDT
|
7.69 M | $ 2.07 | -4.61 % | $ 1.26 M | ||
|
AxoGen
AXGN
|
222 M | $ 31.04 | -5.22 % | $ 1.43 B | ||
|
Align Technology
ALGN
|
6.21 B | $ 172.05 | -2.31 % | $ 12.9 B | ||
|
Integra LifeSciences Holdings Corporation
IART
|
4.04 B | $ 8.93 | -1.92 % | $ 688 M | ||
|
Bruker Corporation
BRKR
|
5.81 B | $ 34.17 | 1.27 % | $ 5.09 K | ||
|
BioSig Technologies
BSGM
|
842 K | - | 37.08 % | $ 85.7 M | ||
|
Apyx Medical Corporation
APYX
|
66.8 M | $ 3.74 | -0.13 % | $ 154 M | ||
|
Second Sight Medical Products
EYES
|
41.6 M | - | -0.97 % | $ 54.4 M | ||
|
Accuray Incorporated
ARAY
|
470 M | $ 0.39 | -0.46 % | $ 40.1 M | ||
|
IRadimed Corporation
IRMD
|
109 M | $ 101.34 | -1.42 % | $ 1.29 B |